Monitor future R&D direction and potential AI/data analytics product announcements; this appointment may signal a long-term strategic pivot toward computational biology, but no near-term financial implications are evident.
Price Chart
Executive Summary
Pacific Biosciences appointed Christopher Gibson, Ph.D., to its Board of Directors and Science and Technology Committee, citing his expertise in AI-driven drug discovery from his role as co-founder and Chairman of Recursion Pharmaceuticals. The move signals a strategic focus on integrating AI and advanced analytics with its HiFi sequencing technology.
Key Facts
- Christopher Gibson, Ph.D., appointed to the Board of Directors effective March 3, 2026
- Dr. Gibson is co-founder and Chairman of Recursion Pharmaceuticals (NASDAQ: RXRX), a clinical-stage biotech with an AI-driven drug discovery platform
- He was also appointed to PacBio's Science and Technology Committee
- No related-party transactions or arrangements disclosed
- Board size increased to ten directors
- No financial terms, compensation details, or immediate strategic changes announced
Financial Impact
No immediate financial impact disclosed
Risk Factors
- Strategic shift into AI integration could increase R&D spending without near-term revenue upside
- Execution risk in leveraging AI effectively within sequencing workflows
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001299130-26-000046 |
| Document: pacb-ex991xchrisgibsonboar.htm | 0001299130-26-000046 |
| Document: 0001299130-26-000046-index-headers.html | 0001299130-26-000046 |
| Document: 0001299130-26-000046-index.html | 0001299130-26-000046 |
| Document: 0001299130-26-000046.txt | 0001299130-26-000046 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $1.84 $2.27 | ▲ +23.10% | ▲ +23.24% | $2.25 (+22.28%) |
Oct 6, 2026 20d ago | 144 | $2.72 $1.99 | ▲ +26.84% | ▲ +25.86% | $2.25 (+17.28%) |
Oct 6, 2026 20d ago | Press Release | $2.70 $2.05 | ▼ −24.07% | ▼ −23.94% | $2.25 (−16.67%) |
Jun 4, 2026 20w ago | 8-K | $1.45 $1.31 | ▼ −9.66% | ▼ −10.22% | $2.25 (+55.17%) |
May 22, 2026 22w ago | DEFA14A | $1.26 $1.58 | ▲ +25.40% | ▲ +24.31% | $2.25 (+78.57%) |
Apr 21, 2026 26w ago | Press Release | $1.73 $1.58 | ▼ −8.67% | ▼ −9.75% | $2.25 (+30.06%) |
Apr 16, 2026 27w ago | Press Release | $1.69 $1.56 | ▼ −7.69% | ▼ −8.25% | $2.25 (+33.14%) |
Mar 5, 2026 33w ago | 8-K | $1.52 $1.27 | ▼ −16.45% | ▼ −14.21% | $2.25 (+48.03%) |
Mar 3, 2026 33w ago | Insider Cluster | $1.52 $1.37 | ▼ −9.87% | ▼ −9.39% | $2.25 (+48.03%) |
Feb 28, 2026 34w ago | Institutional Cluster | $1.62 $1.39 | ▼ −14.20% | ▼ −12.99% | $2.25 (+38.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers